TCEA3 Antibody (Center) Blocking Peptide
- Known as:
- TCEA3 Antibody (Center) Blocking Peptide
- Catalog number:
- BP16463c
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- TCEA3 Antibody (Center) Blocking Peptide
Related genes to: TCEA3 Antibody (Center) Blocking Peptide
- Gene:
- TCEA3 NIH gene
- Name:
- transcription elongation factor A3
- Previous symbol:
- -
- Synonyms:
- TFIIS.H
- Chromosome:
- 1p36.12
- Locus Type:
- gene with protein product
- Date approved:
- 1998-05-01
- Date modifiied:
- 2016-10-05
Related products to: TCEA3 Antibody (Center) Blocking Peptide
Related articles to: TCEA3 Antibody (Center) Blocking Peptide
- The cross-species integration of mouse kidney multi-omics and human genome-wide association study identified 46 cross-species urolithiasis-related molecules. Cell type enrichment suggested that immune cells and collecting duct principal cells may play roles in urolithiasis pathophysiology. Follow-up analyses using human renal data, colocalization, and Mendelian randomization supported the relevance of the detected 46 molecules in humans. - Source: PubMed
Publication date: 2026/06/11
Chaya RyosukeTaguchi KazumiHashimoto YutakaShirai YuyaEdahiro RyuyaSasa NoahYamamoto KenichiTomofuji YoshihiroNamba ShinichiSonehara KyutoUnno ReiHamamoto ShuzoOkada AtsushiMuroski JohnKato YoichiCristea Ileana MOkada YukinoriYasui Takahiro - Biliary atresia (BA) is a rare pediatric cholestatic disorder characterized by progressive bile duct inflammation and fibrosis. The underlying molecular mechanisms of BA remain poorly defined. This study aimed to identify susceptibility genes causally associated with BA by integrating genome-wide association study (GWAS) and transcriptomic data, and to explore their potential immunopathological roles. - Source: PubMed
Publication date: 2025/07/15
Lv ChaoQi ChengangDai XiaokeZhang Mingman - Gastric cancer (GC) is a widespread cancerous disease with an unfavorable prognosis, linc01105 appears to have a significant connection with the development of GC, but the precise regulatory mechanism remains obscure. Real-time quantitative polymerase chain reaction (RT-qPCR) was utilized to determine the expression of linc01105, miR-650, and TCEA3. Proliferative capacity of GC cells was measured by CCK8. Cell apoptosis rates were analyzed via flow cytometry assessment. The invasive capability was assessed through the Transwell experiment. The targeted regulation of linc01105, miR-650, and TCEA3 was validated through dual luciferase reporter gene assay. Low expression of linc01105, high expression of miR-650, and low expression of TCEA3 were observed in GC tumor tissues and cell lines. High expression of linc01105 was correlated with a positive prognosis in GC patients. linc01105 affected GC cell function by miR-650/TCEA3 axis. This study suggested that linc01105 may possess inhibitory functions towards GC. In addition, linc01105 may be a prognostic marker for GC. - Source: PubMed
Zhang QiangMi HuiCai HuimeiLi ChenhuiWu ZhouZhang Jianfang - Osteosarcoma (OS) remains the most common bone tumor and the prognosis for many patients remains stagnant due to the unsatisfactory therapeutic effect of conventional treatment regimens. This research explored the effect and mechanism of a novel natural product, Eriocalyxin B (EB), in pathogenesis and immunotherapy in OS. Cell Count Kit 8 assay, colony formation assay, and wound healing assay were employed to detect the proliferative, colony-forming, and migratory abilities of human OS cells following EB treatment. Moreover, xenograft growth assay was performed to assess the effect of EB on OS in vivo. Subcutaneous OS models constructed in immunocompetent mice were employed to evaluate the effect of EB treatment in combination with immune checkpoint blockades (ICBs) PD1ab and CTLA4ab. Immunohistochemistry (IHC) staining was utilized to detect the level of CD8+ T cells infiltration and Ki67 expression. TARGET database, RNA interference technology, and qPCR assay were employed to explore the mechanism of EB on OS. EB inhibited the proliferative, colony-forming, and migratory abilities of the human OS cells MG63 and U2OS both in vitro and in vivo. TARGET data analysis demonstrated that up-regulation of TCEA3 was significantly negatively correlated with overall survival in OS patients. EB exerted anti-tumor activity via downregulation of TCEA3. EB, in conjunction with ICBs, synergistically optimized anti-tumorigenic activity against OS in immunocompetent mice. EB may promote infiltration of CD8+ T cells and down-regulate Ki67 expression. These results signaled that EB may have a role as a candidate therapeutic or preventive agent for the treatment of OS. - Source: PubMed
Publication date: 2025/01/31
Zeng Ling-QiChen Mu-LanFang Bin-BoChen Jun-Ze - Lung cancer is a prevalent and severe form of malignant tumors worldwide. tRF-Leu-CAG, a recently discovered non-coding single-stranded small RNA derived from transfer RNA, has sparked interest in exploring its biological functions and potential molecular mechanisms in lung cancer. - Source: PubMed
Wu FanChai BinshuQi PengfeiHan YaqiGu ZhitaoPan WeiZhang HuiWang XianyiLiu XiaominZou HengLiang ChenLi YanLiFang WentaoMa Zhongliang